دورية أكاديمية

Tolerance and preliminary results of simultaneous therapy with radiation and cisplatin for advanced cervical cancer.

التفاصيل البيبلوغرافية
العنوان: Tolerance and preliminary results of simultaneous therapy with radiation and cisplatin for advanced cervical cancer.
المؤلفون: Monyak DJ; Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Hospital, Minneapolis 55455., Twiggs LB, Potish RA, Adcock LL, Savage JE, Downey GO, Carson LF, Prem KA
المصدر: NCI monographs : a publication of the National Cancer Institute [NCI Monogr] 1988 (6), pp. 369-73.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: U.S. National Cancer Institute Country of Publication: United States NLM ID: 8610384 Publication Model: Print Cited Medium: Print ISSN: 0893-2751 (Print) Linking ISSN: 08932751 NLM ISO Abbreviation: NCI Monogr Subsets: MEDLINE
أسماء مطبوعة: Publication: Bethesda Md : U.S. National Cancer Institute
Original Publication: [Bethesda, Md.] : U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, [1986-1990]
مواضيع طبية MeSH: Cisplatin/*therapeutic use , Uterine Cervical Neoplasms/*therapy, Adult ; Aged ; Cisplatin/adverse effects ; Combined Modality Therapy ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Radiotherapy/adverse effects ; Uterine Cervical Neoplasms/mortality
مستخلص: From 1982 through 1985, 49 women with advanced cervical cancer were treated with concurrent radiation and cisplatin to assess tolerance to the combined modality regimen and its efficacy in comparison to historical controls at the same institution. Eligibility criteria included clinical stage IV disease; para-aortic lymph node metastases; and bilateral, unresectable, and/or multiple (greater than 3) pelvic node metastases. Nodal status was assessed by extraperitoneal surgical staging in the majority of patients with clinical stage I-IVA disease. There was no increase in acute or chronic toxicity compared to historical controls. No patient required reduction of the planned dose of radiation because of acute toxicity. Comparison with historical controls suggests a modest improvement in relapse-free survival in the cisplatin-treated group with positive para-aortic nodes (59% vs. 54% at 2 yr and 59% vs. 42% at 3 yr). We conclude that adjuvant cisplatin can be given simultaneously with radiation for advanced cervical cancer without excessive toxicity or compromise of the radiation regimen. However, confirmation of the modest improvement in relapse-free survival rates for patients with positive para-aortic nodes and identification of other subsets of patients who may benefit will require a prospective randomized trial.
المشرفين على المادة: Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 19880101 Date Completed: 19880503 Latest Revision: 20131121
رمز التحديث: 20240627
PMID: 3352786
قاعدة البيانات: MEDLINE